
|Videos|July 6, 2017
Axel Hoos on the ATOM Initiative
Author(s)Axel Hoos, M.D., Ph.D.
Axel Hoos, M.D., Ph.D. of GlaxoSmithKline discusses the ATOM Initiative.
Advertisement
Axel Hoos, M.D., Ph.D., Head of Oncology of GlaxoSmithKline (GSK), discusses the ATOM Initiative.
Joining with the Department of Energy and the National Cancer Insitute, GSK is working on in silico screening. The ATOM Initiative uses a super-computer, owned by the Department of Energy to rapidly identify potential new pharmacuetical agents to target cancer. This super-computer can screen the compounds much faster than any other computer that exists. This initiative is still in the pilot stage as it is a completely novel concept.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
What Patients With Cancer Should Know About Radiation Side Effects
2
I’m Still Here: My Fight Against Colorectal Cancer
3
FDA Grants Rare Pediatric Designation for Iopofosine-131 in Glioma Subset
4
Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer
5





